Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LFB083
- Development stage
- Preclinical
- Lead developer
- Leapfrog Bio
- Modality
- Small Molecules
01
Overview
LFB083 is a small molecule drug candidate being developed by Leapfrog Bio that targets a synthetic lethality relationship with PIK3CA gain-of-function mutations. Identified through the OncoSLX platform, which screens shelved or deprioritized pharmaceutical assets, LFB083 is designed to inhibit PIK3CA-mutant driven PI3K signaling. The compound has a clinical history, having been previously tested and shown to be safe in approximately 100 unselected patients. It is currently in the IND-enabling phase of development, with a focus on treating breast cancer and other genetically defined PIK3CA-mutant cancers. The drug is expected to be IND-ready in 2027.
02
Targets
Beyond the preview
Go deeper on LFB083.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LFB083.